Who is sponsoring NCT05310929?

NCT05310929 is sponsored by Ain Shams University.

What drugs are being tested in NCT05310929?

Interventions in NCT05310929: Labetalol and Glyceril trinitrate.

What condition does NCT05310929 study?

NCT05310929 studies Severe Pre-eclampsia.

Is NCT05310929 still recruiting?

NCT05310929 is currently completed. Last updated 5 April 2022.

Last reviewed 2022-04-05 · How we verify

NCT05310929

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia

Completed NA Last updated 5 April 2022

What this trial tests

NA trial testing Labetalol and Glyceril trinitrate in Severe Pre-eclampsia in 200 participants. Completed in 25 March 2022.

Timeline

28 August 2019

Primary endpoint
20 March 2022

25 March 2022

Quick facts

Lead sponsor	Ain Shams University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	28 August 2019
Primary completion	20 March 2022
Estimated completion	25 March 2022
Sites	1 location across Egypt

Drugs / interventions tested

Labetalol and Glyceril trinitrate — full drug profile →

Conditions studied

Severe Pre-eclampsia — all drugs for Severe Pre-eclampsia →

Sponsor

Ain Shams University

Who can join

Adults 18 to 40, female only, with Severe Pre-eclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Two hundred patients with severe PE were admitted prepartum to the ICU to stabilize blood pressure. They were randomly assigned to one of two groups (100 in each group): Group N received nitroglycerine intravenous infusion in a concentration of 1 mg/ml, thus 1µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient. Group L received labetalol intravenous infusion in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication was 5 ml/hr. The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point) by adjusting the infusion rate as required either by maintaining the same infusion rate or by changing its infusion rate by 1 ml/hr up or down according to the clinical condition every 10 minutes. On any abrupt reduction in blood pressure below 120 mmHg for SBP or 80 mmHg for DBP, the infusion was immediately discontinued, and a bolus of 150 ml lactate ringer was given.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacotherapeutic options for the treatment of hypertension in pregnancy.
Conti-Ramsden F, de Marvao A, Chappell LC. · · 2024 · cited 4× · PMID 39225514 · DOI 10.1080/14656566.2024.2398602

Verify or expand the search:

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05310929 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 5 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05310929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing